Finanzen von Carlsmed, Inc. (CARL)CARLCarlsmed, Inc.

Evaluating the bottom line, Carlsmed, Inc. maintains a gross margin of 76.78%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -58.27%, while the net margin is -55.49%. These profitability ratios, combined with a Return on Equity (ROE) of -6196.93%, provide a clear picture of how effectively CARL converts its operational activities into shareholder value.

In the context of the broader market, CARL competes directly with industry leaders such as RMNI and CINT. With a market capitalization of $403.53M, it holds a leading position in the sector. When comparing efficiency, CARL's gross margin of 76.78% stands against RMNI's 60.95% and CINT's 31.09%. Such benchmarking helps identify whether Carlsmed, Inc. is trading at a premium or discount relative to its financial performance.

Carlsmed's revenue has shown strong growth, with Q2 2026 revenue of $18.9 million, exceeding expectations and reflecting a 57% increase from the previous year. However, the company is still facing net losses, which reached $10.5 million in Q2 2026.